Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:860-865

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zaman, A. G.
Right arrow Articles by Badimon, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaman, A. G.
Right arrow Articles by Badimon, J. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
*HEPARIN
Related Collections
Right arrow Anticoagulant mechanisms
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:860.)
© 2000 American Heart Association, Inc.


Thrombosis

In Vivo Dynamic Real-Time Monitoring and Quantification of Platelet-Thrombus Formation

Use of a Local Isotope Detector

Azfar G. Zaman; Julio I. Osende; James H. Chesebro; Valentin Fuster; Adrian Padurean; Richard Gallo; Stephen G. Worthley; Gerard Helft; Oswaldo X. Rodriguez; John T. Fallon; Juan J. Badimon

From the Cardiovascular Biology Research Laboratory (A.G.Z., J.I.O., V.F., S.G.W., G.H., O.X.R., J.J.B.), Zena and Michael A. Wiener Cardiovascular Institute (J.H.C., V.F., J.J.B.), and the Department of Pathology (J.T.F.), Mount Sinai School of Medicine, New York, NY; Regions Hospital (A.P.), St. Paul, Minn; and Montreal Heart Institute (R.G.), Montreal, Canada.

Correspondence to Dr J.J. Badimon, Director, Cardiovascular Biology Research Laboratory, Zena and Michael A. Wiener Cardiovascular Institute, Box 1030, Mount Sinai School of Medicine, New York, NY 10029-6574. E-mail jbadimo{at}smtplink.mssm.edu

Abstract—Current methods for monitoring thrombosis and thrombus growth are invasive and provide only single–time-point data. Animal models rely mainly on flow changes as a surrogate of thrombus formation. Our aim was to validate a unique potentially noninvasive system to detect and quantify dynamic thrombus formation in vivo by using a porcine model of carotid artery injury. Thrombus growth was monitored by deposition of autologous 111In-labeled platelet activity over the injured artery by use of miniaturized gamma detectors and Doppler blood flow. Counts were recorded at 2-minute intervals for 2 hours. The technique was validated by comparing standard antithrombotic agents against controls. Platelet recruitment was detected before significant change in flow. Thrombus formation, calculated as the area under the curve (plateletsxminutesx106), was greatest for control animals (11.7±1.28), followed by animals treated with aspirin (6.13±0.91, P<0.05), heparin (2.45±0.34, P<0.05), and hirudin (0.2±0.01, P<0.01 compared with heparin). The rate of platelet deposition was assessed as the slope of the curve in the first 30 minutes (plateletsx106 per minute) for the following treatment groups of animals: control, 3.53±0.34; aspirin, 1.67±0.34 (P<0.01); heparin, 1.55±0.3 (P<0.01); and hirudin, 0.25±0.03 (P<0.001). There was no statistical difference between heparin and aspirin treatments. Change in flow was assessed as reduction from baseline: control, >99±0.34%; aspirin, 39±9.1%; heparin, 36±12.5%; and hirudin, 17±5.4%. There was no statistical difference between the aspirin- and heparin-treated groups. Morphometric analysis revealed >99±0.63% occlusion of the luminal area with thrombus for the control group, 43±14.3% for the aspirin-treated group, 30±5.6% for the heparin-treated group, and <10±1.8% for the hirudin-treated group. Assessment of platelet-thrombus formation with this technique was more sensitive than change in flow in determining antithrombotic efficacy, and thrombus formation was detected earlier. This study validates a new quantitative, sensitive, potentially noninvasive, portable, in vivo monitoring of dynamic thrombus growth, which appears applicable to phase II studies in humans.


Key Words: platelets • thrombus • antithrombotics • radioisotopes




This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
V. Kozlovaite, P. Grybauskas, J. Cimbolaityte, A. Mongirdiene, A. Puodziukynas, T. Kazakevicius, and J. Ptasekas
Influence of Radiofrequency Catheter Ablation on Platelet Aggregation
Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 416 - 421.
[Abstract] [PDF]


Home page
CirculationHome page
M. Sirol, V. Fuster, J. J. Badimon, J. T. Fallon, J.-F. Toussaint, and Z. A. Fayad
Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent
Circulation, September 13, 2005; 112(11): 1594 - 1600.
[Abstract] [Full Text] [PDF]